Teladoc Health, Inc. (NYSE:TDOC) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank trimmed its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC – Get Rating) by 82.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,492 shares of the health services provider’s stock after selling 34,110 shares during the period. Toronto Dominion Bank’s holdings in Teladoc Health were worth $177,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. MetLife Investment Management LLC acquired a new position in Teladoc Health during the 1st quarter worth approximately $218,000. Panagora Asset Management Inc. raised its stake in shares of Teladoc Health by 18.8% during the first quarter. Panagora Asset Management Inc. now owns 16,710 shares of the health services provider’s stock valued at $1,205,000 after purchasing an additional 2,640 shares during the period. Rhumbline Advisers lifted its position in shares of Teladoc Health by 2.3% during the first quarter. Rhumbline Advisers now owns 130,916 shares of the health services provider’s stock worth $9,443,000 after purchasing an additional 2,921 shares in the last quarter. Great West Life Assurance Co. Can grew its holdings in Teladoc Health by 10.8% during the 1st quarter. Great West Life Assurance Co. Can now owns 107,908 shares of the health services provider’s stock valued at $8,237,000 after purchasing an additional 10,559 shares in the last quarter. Finally, Raymond James Trust N.A. increased its stake in Teladoc Health by 7.8% during the 1st quarter. Raymond James Trust N.A. now owns 11,451 shares of the health services provider’s stock worth $826,000 after buying an additional 827 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on TDOC shares. VNET Group reissued a “maintains” rating on shares of Teladoc Health in a research report on Thursday, April 27th. Citigroup dropped their price objective on Teladoc Health from $33.00 to $30.00 and set a “neutral” rating on the stock in a report on Tuesday, February 28th. Wells Fargo & Company reduced their target price on Teladoc Health from $28.00 to $23.00 and set an “equal weight” rating for the company in a research note on Monday, March 6th. SVB Securities upgraded shares of Teladoc Health from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a research note on Thursday, February 23rd. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Teladoc Health from $27.00 to $29.00 in a research note on Friday, April 28th. One research analyst has rated the stock with a sell rating, seventeen have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Teladoc Health currently has an average rating of “Hold” and a consensus target price of $32.78.

Insiders Place Their Bets

In other news, insider Vidya Raman-Tangella sold 15,372 shares of the company’s stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of $26.76, for a total value of $411,354.72. Following the completion of the sale, the insider now owns 25,620 shares in the company, valued at $685,591.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Vidya Raman-Tangella sold 15,372 shares of the stock in a transaction that occurred on Tuesday, May 2nd. The shares were sold at an average price of $26.76, for a total transaction of $411,354.72. Following the completion of the sale, the insider now directly owns 25,620 shares of the company’s stock, valued at $685,591.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Daniel Trencher sold 1,000 shares of the firm’s stock in a transaction on Friday, February 17th. The stock was sold at an average price of $30.21, for a total value of $30,210.00. Following the sale, the senior vice president now directly owns 20,408 shares of the company’s stock, valued at $616,525.68. The disclosure for this sale can be found here. Insiders sold 58,423 shares of company stock worth $1,521,260 over the last ninety days. Company insiders own 1.63% of the company’s stock.

Teladoc Health Price Performance

Shares of NYSE:TDOC opened at $24.85 on Friday. The firm’s 50 day moving average is $25.66 and its two-hundred day moving average is $26.90. The firm has a market capitalization of $4.07 billion, a P/E ratio of -0.57 and a beta of 1.08. The company has a current ratio of 3.37, a quick ratio of 3.25 and a debt-to-equity ratio of 0.67. Teladoc Health, Inc. has a 52 week low of $21.60 and a 52 week high of $44.66.

Teladoc Health (NYSE:TDOC – Get Rating) last released its earnings results on Wednesday, February 22nd. The health services provider reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.04. The firm had revenue of $637.71 million for the quarter, compared to analysts’ expectations of $633.71 million. Teladoc Health had a negative net margin of 285.51% and a negative return on equity of 5.81%. Analysts anticipate that Teladoc Health, Inc. will post -1.4 earnings per share for the current year.

Teladoc Health Company Profile

(Get Rating)

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services.